Keros Therapeutics Stock (NASDAQ:KROS)


ForecastChart

Previous Close

$13.53

52W Range

$9.12 - $72.37

50D Avg

$11.14

200D Avg

$36.44

Market Cap

$570.71M

Avg Vol (3M)

$1.19M

Beta

1.39

Div Yield

-

KROS Company Profile


Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

169

IPO Date

Apr 08, 2020

Website

KROS Performance


Peer Comparison


TickerCompany
NGMNGM Biopharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
ANABAnaptysBio, Inc.
IDYAIDEAYA Biosciences, Inc.
FENCFennec Pharmaceuticals Inc.
KZRKezar Life Sciences, Inc.
FIXXQ32 Bio Inc.
MGTXMeiraGTx Holdings plc
REPLReplimune Group, Inc.